Corvex Management LP

Director Meister buys 351,273 shares across 6 trades for $13.8M (avg $39.19) as stock falls 76.2% from 52-week high

Director Keith A. Meister executed 6 separate open-market purchases totaling 351,273 shares for $13,765,344.69 over three days (May 13–15, 2026), raising his holdings from 4,433,297 to 4,784,570 shares. The purchases occurred as the stock was in sharp decline, trading at $40.75 currently, which is -76.2% from the 52-week high of $170.87, and down -39.6% over the prior 30 days and -54.8% over 90 days. Across his 5 prior trades at WGS, Meister's timing outcomes were mixed: only 2 of 5 prior buys yielded positive 90-day returns. The company is unprofitable with net income of $-63,316,000.00 against revenue of $102,254,000.00 (latest quarter), though it shows annual revenue growth of +40.0%. The scale and timing of this multi-transaction purchase in a volatile, unprofitable biotech context warrant attention to underlying company conditions and Meister's conviction in the recovery thesis.

Director Meister acquires over 1.2M shares across 13 transactions; stock down 76% from 52-week high amid unprofitable operations and poor timing history at this ticker.

Keith Meister, a director and 10% beneficial owner of GeneDx, deployed substantial capital across 13 open-market purchases in early May, acquiring over 1.2 million shares at prices ranging from the mid-$35s to low-$41s. The stock is trading well below its 52-week high and has declined significantly over recent months, creating a classic "buying the dip" scenario. However, Meister's track record at this specific company is concerning: all five of his prior purchases at GeneDx in March yielded substantial subsequent declines over both the 30-day and 90-day periods that followed, and his broader insider track record across all securities shows minimal success with open-market buys. Additionally, GeneDx remains unprofitable with operating losses in its latest quarter despite year-over-year revenue growth, raising questions about whether the steep discount reflects genuine value or deteriorating fundamentals. This filing is notable primarily as a test of whether an insider with a poor historical timing record can successfully identify a bottom in a stock already down substantially from recent highs.

Director Keith A. Meister purchased 169,521 shares ($13.5M) at GeneDx across 10 transactions on 2026-03-03/05, raising holdings to 3.23M shares (+5.5%).

Director Meister executed 10 separate purchases totaling 169,521 shares for $13,460,089.63 at an average price of $79.40 over two trading days (2026-03-03 to 2026-03-05), significantly expanding a position already representing substantial company ownership. This transaction occurs as the stock trades at $82.00, down 51.0% from its 52-week high of $167.52 and down 13.9% over the past 30 days, yet Meister's prior trades at this ticker show a perfect 5 of 5 win rate at the 90-day mark with returns ranging from +84.0% to +94.6%. The company carries a negative full-year net income of $-7,635,000.00 despite strong revenue growth of 40.0% year-over-year, trading at a P/E of 71.93 on a $2.4B market cap. The scale and deliberate multi-tranche execution of this purchase, combined with Meister's consistent success timing WGS buys in the past, provides a meaningful signal regarding insider conviction during a period of significant stock weakness.

Director Meister Keith A. bought 1,010,064 shares for $6,874,339.00 at Vestis Corp (VSTS) in two transactions on 2025-12-16 and 2025-12-17.

Keith A. Meister, a director of Vestis Corp, executed 2 separate open-market purchases totaling 1,010,064 shares for $6,874,339.00 at a blended average price of $6.81 per share on consecutive trading days. The transactions increased his holdings by 5.4% to 19,813,963 shares post-transaction. At the time of purchase, the stock was -57.7% from its 52-week high of $16.45 and has risen 34.4% over the past 30 days and 67.7% over the past 90 days from the transaction dates. Notably, a cluster pattern is present—2 other insiders also bought within the past 14 days. However, Meister's own prior trading history at VSTS shows 0 of 5 prior buys were well-timed at the 90-day mark, with cumulative 90-day underperformance. The company generated $673.8M in revenue in the latest quarter but remains unprofitable with negative full-year net income and declining year-over-year revenue of -2.5%.